{
    "info": {
        "nct_id": "NCT05681780",
        "official_title": "Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)",
        "inclusion_criteria": "* Age greater than or equal to 18 years\n* Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with an activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains\n* ECOG performance status of 0 or 1\n* Expected survival ≥ 4 months\n* Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC, including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration, prior to initiating nivolumab trial therapy\n* Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy\n* In accordance with the criteria above, safely accessible tumor for TIL harvest by excisional biopsy expected to yield 1.5 cm3 of tissue, in aggregate\n* Participants with known brain metastases are eligible for study enrollment if the brain metastases have received appropriate central nervous system-directed therapy or are found to be clinically stable ≤ 10 mm when comparing scans obtained during the screening period with a scan obtained ≥28 days prior, or if the treating physician determines that immediate CNS-specific treatment is not required prior to the first cycle of therapy. Please also refer to eligibility section on corticosteroids below.\n* Adequate normal organ and marrow function as defined below:\n* a. Hemoglobin ≥ 9.0 g/dL, with transfusions permissible;\n* b. Absolute neutrophil count (ANC) ≥ 1000 per mm3);\n* c. Platelet count ≥ 75,000 per mm3, without platelet transfusions for 7 days;\n* d. Prothrombin Time ≤ 1.7x the institutional upper limit of normal (ULN), unless participant is receiving intended anticoagulant therapy.\n* e. Serum bilirubin ≤ 2.0x the institutional ULN, or ≤ 4.0x ULN if confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology) with PI approval.\n* f. AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN\n* g. Serum creatinine of ≤ 1.5x institutional ULN, or ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN\n* h. Albumin ≥ 2.0 g/dl\n* Pulmonary function tests within past 4 months showing DLCO ≥45% of predicted. Adjusted DLCO based on hemoglobin concentration should be used, if available.\n* Human immunodeficiency virus (HIV)-infected participants must be receiving on effective antiretroviral therapy for past 6 months with undetectable viral load and normal CD4 count\n* Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy, if indicated, and no overt cirrhosis\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they must have an undetectable HCV viral load and no overt cirrhosis\n* Participants with a prior or concurrent malignancy must have a natural history which does not have the potential to interfere with safety or efficacy assessment of the investigational regimen\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* No more than six prior lines of systemic therapy for NSCLC\n* No prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC. Examples of inhibitors include: nivolumab, atezolizumab, pembrolizumab, avelumab, cemplimumab, spartalizumab, or durvalumab.\n* Participants with rapidly progressing tumors, as judged by the investigator\n* Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years), or other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI\n* Active leptomeningeal or pachymeningeal metastases, or carcinomatous meningitis. This is due to prognostic implications and timeline for cell therapy\n* Has a diagnosis of primary immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.\n* a. Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose\n* b. Inhaled, intranasal, or topical corticosteroids are permitted\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation or supraventricular tachycardia), and significant ≥85% carotid artery stenosis\n* Unresolved toxicity (grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)\n* Mean QT interval corrected for heart rate (QTc) ≥480 ms calculated from electrocardiograms (EKGs) using Bazett's Correction\n* Participants with active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab. Prophylactic, empiric, or suppressive antibiotics are permitted with sponsor approval\n* History of allogeneic organ transplant\n* Participants with psychiatric illness/social situations that would limit compliance with study requirements\n* Participants with a history of anaphylaxis to beta-lactam antibiotics. Patients may be evaluated for reported history by conducting a history and physical, and a skin test/challenge where appropriate under medical guidance",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Participants with a prior or concurrent malignancy must have a natural history which does not have the potential to interfere with safety or efficacy assessment of the investigational regimen",
                "criterions": [
                    {
                        "exact_snippets": "Participants with a prior or concurrent malignancy",
                        "criterion": "prior or concurrent malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have a natural history which does not have the potential to interfere with safety or efficacy assessment of the investigational regimen",
                        "criterion": "natural history of malignancy",
                        "requirement": {
                            "requirement_type": "potential to interfere with safety or efficacy assessment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Participants with a prior or concurrent malignancy",
                    "criterion": "prior or concurrent malignancy",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "must have a natural history which does not have the potential to interfere with safety or efficacy assessment of the investigational regimen",
                    "criterion": "natural history of malignancy",
                    "requirement": {
                        "requirement_type": "potential to interfere with safety or efficacy assessment",
                        "expected_value": false
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Age greater than or equal to 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age greater than or equal to 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age greater than or equal to 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* g. Serum creatinine of ≤ 1.5x institutional ULN, or ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine of ≤ 1.5x institutional ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine levels >1.5 × institutional ULN ... ≥30 mL/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum creatinine of ≤ 1.5x institutional ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine levels >1.5 × institutional ULN ... ≥30 mL/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Human immunodeficiency virus (HIV)-infected participants must be receiving on effective antiretroviral therapy for past 6 months with undetectable viral load and normal CD4 count",
                "criterions": [
                    {
                        "exact_snippets": "Human immunodeficiency virus (HIV)-infected participants",
                        "criterion": "HIV infection status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must be receiving on effective antiretroviral therapy for past 6 months",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": "effective antiretroviral therapy"
                        }
                    },
                    {
                        "exact_snippets": "must be receiving on effective antiretroviral therapy for past 6 months",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "undetectable viral load",
                        "criterion": "HIV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    },
                    {
                        "exact_snippets": "normal CD4 count",
                        "criterion": "CD4 count",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Human immunodeficiency virus (HIV)-infected participants",
                        "criterion": "HIV infection status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must be receiving on effective antiretroviral therapy for past 6 months",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "treatment",
                            "expected_value": "effective antiretroviral therapy"
                        }
                    },
                    {
                        "exact_snippets": "must be receiving on effective antiretroviral therapy for past 6 months",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "undetectable viral load",
                        "criterion": "HIV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    },
                    {
                        "exact_snippets": "normal CD4 count",
                        "criterion": "CD4 count",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with known brain metastases are eligible for study enrollment if the brain metastases have received appropriate central nervous system-directed therapy or are found to be clinically stable ≤ 10 mm when comparing scans obtained during the screening period with a scan obtained ≥28 days prior, or if the treating physician determines that immediate CNS-specific treatment is not required prior to the first cycle of therapy. Please also refer to eligibility section on corticosteroids below.",
                "criterions": [
                    {
                        "exact_snippets": "Participants with known brain metastases are eligible for study enrollment",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "brain metastases have received appropriate central nervous system-directed therapy",
                        "criterion": "central nervous system-directed therapy for brain metastases",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "brain metastases ... are found to be clinically stable ≤ 10 mm when comparing scans obtained during the screening period with a scan obtained ≥28 days prior",
                        "criterion": "brain metastases size stability",
                        "requirement": {
                            "requirement_type": "size_change",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "mm"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "if the treating physician determines that immediate CNS-specific treatment is not required prior to the first cycle of therapy",
                        "criterion": "need for immediate CNS-specific treatment",
                        "requirement": {
                            "requirement_type": "immediacy_of_treatment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants with known brain metastases are eligible for study enrollment",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "brain metastases have received appropriate central nervous system-directed therapy",
                                "criterion": "central nervous system-directed therapy for brain metastases",
                                "requirement": {
                                    "requirement_type": "receipt",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants with known brain metastases are eligible for study enrollment",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "brain metastases ... are found to be clinically stable ≤ 10 mm when comparing scans obtained during the screening period with a scan obtained ≥28 days prior",
                                "criterion": "brain metastases size stability",
                                "requirement": {
                                    "requirement_type": "size_change",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 10,
                                                "unit": "mm"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants with known brain metastases are eligible for study enrollment",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "if the treating physician determines that immediate CNS-specific treatment is not required prior to the first cycle of therapy",
                                "criterion": "need for immediate CNS-specific treatment",
                                "requirement": {
                                    "requirement_type": "immediacy_of_treatment",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* In accordance with the criteria above, safely accessible tumor for TIL harvest by excisional biopsy expected to yield 1.5 cm3 of tissue, in aggregate",
                "criterions": [
                    {
                        "exact_snippets": "safely accessible tumor for TIL harvest by excisional biopsy",
                        "criterion": "tumor",
                        "requirement": {
                            "requirement_type": "accessibility for TIL harvest by excisional biopsy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "expected to yield 1.5 cm3 of tissue, in aggregate",
                        "criterion": "tumor tissue yield",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm3"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "safely accessible tumor for TIL harvest by excisional biopsy",
                        "criterion": "tumor",
                        "requirement": {
                            "requirement_type": "accessibility for TIL harvest by excisional biopsy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "expected to yield 1.5 cm3 of tissue, in aggregate",
                        "criterion": "tumor tissue yield",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm3"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate normal organ and marrow function as defined below:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate normal organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate normal organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "normality",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate normal organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate normal organ and marrow function",
                        "criterion": "organ and marrow function",
                        "requirement": {
                            "requirement_type": "normality",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they must have an undetectable HCV viral load and no overt cirrhosis",
                "criterions": [
                    {
                        "exact_snippets": "history of hepatitis C virus (HCV) infection ... must have been treated and cured",
                        "criterion": "hepatitis C virus (HCV) infection history",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "treated and cured"
                        }
                    },
                    {
                        "exact_snippets": "participants with HCV infection who are currently on treatment ... must have an undetectable HCV viral load",
                        "criterion": "HCV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "participants with HCV infection who are currently on treatment ... no overt cirrhosis",
                        "criterion": "overt cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "history of hepatitis C virus (HCV) infection ... must have been treated and cured",
                        "criterion": "hepatitis C virus (HCV) infection history",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "treated and cured"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "participants with HCV infection who are currently on treatment ... must have an undetectable HCV viral load",
                                "criterion": "HCV viral load",
                                "requirement": {
                                    "requirement_type": "detectability",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "participants with HCV infection who are currently on treatment ... no overt cirrhosis",
                                "criterion": "overt cirrhosis",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* ECOG performance status of 0 or 1",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status of 0 or 1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status of 0 or 1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy, if indicated, and no overt cirrhosis",
                "criterions": [
                    {
                        "exact_snippets": "history of chronic hepatitis B virus (HBV) infection",
                        "criterion": "chronic hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have undetectable HBV viral load",
                        "criterion": "HBV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    },
                    {
                        "exact_snippets": "on suppressive therapy, if indicated",
                        "criterion": "suppressive therapy for HBV",
                        "requirement": {
                            "requirement_type": "use if indicated",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "no overt cirrhosis",
                        "criterion": "overt cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "history of chronic hepatitis B virus (HBV) infection",
                    "criterion": "chronic hepatitis B virus (HBV) infection",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "must have undetectable HBV viral load",
                            "criterion": "HBV viral load",
                            "requirement": {
                                "requirement_type": "detectability",
                                "expected_value": "undetectable"
                            }
                        },
                        {
                            "exact_snippets": "on suppressive therapy, if indicated",
                            "criterion": "suppressive therapy for HBV",
                            "requirement": {
                                "requirement_type": "use if indicated",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "no overt cirrhosis",
                            "criterion": "overt cirrhosis",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "lesion exclusion",
                            "expected_value": "not including any lesion that is used for TIL harvest"
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to initiation of nivolumab trial therapy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "lesion exclusion",
                            "expected_value": "not including any lesion that is used for TIL harvest"
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to initiation of nivolumab trial therapy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC, including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration, prior to initiating nivolumab trial therapy",
                "criterions": [
                    {
                        "exact_snippets": "Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC",
                        "criterion": "disease progression after prior systemic therapy for NSCLC",
                        "requirement": {
                            "requirement_type": "history of disease progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC",
                        "criterion": "disease progression after prior systemic therapy for NSCLC",
                        "requirement": {
                            "requirement_type": "number of prior lines of systemic therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration",
                        "criterion": "prior targeted therapy for actionable genomic alteration",
                        "requirement": {
                            "requirement_type": "receipt of appropriate prior targeted therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration",
                        "criterion": "prior targeted therapy for actionable genomic alteration",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": "if a targeted therapy is conventionally used for this genomic alteration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC",
                                "criterion": "disease progression after prior systemic therapy for NSCLC",
                                "requirement": {
                                    "requirement_type": "history of disease progression",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC",
                                "criterion": "disease progression after prior systemic therapy for NSCLC",
                                "requirement": {
                                    "requirement_type": "number of prior lines of systemic therapy",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "line"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "condition": {
                            "exact_snippets": "including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration",
                            "criterion": "prior targeted therapy for actionable genomic alteration",
                            "requirement": {
                                "requirement_type": "applicability",
                                "expected_value": "if a targeted therapy is conventionally used for this genomic alteration"
                            }
                        },
                        "then_criteria": {
                            "exact_snippets": "including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration",
                            "criterion": "prior targeted therapy for actionable genomic alteration",
                            "requirement": {
                                "requirement_type": "receipt of appropriate prior targeted therapy",
                                "expected_value": true
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Active leptomeningeal or pachymeningeal metastases, or carcinomatous meningitis. This is due to prognostic implications and timeline for cell therapy",
                "criterions": [
                    {
                        "exact_snippets": "Active leptomeningeal or pachymeningeal metastases",
                        "criterion": "leptomeningeal metastases",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active leptomeningeal or pachymeningeal metastases",
                        "criterion": "pachymeningeal metastases",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "carcinomatous meningitis",
                        "criterion": "carcinomatous meningitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Active leptomeningeal or pachymeningeal metastases",
                        "criterion": "leptomeningeal metastases",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active leptomeningeal or pachymeningeal metastases",
                        "criterion": "pachymeningeal metastases",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "carcinomatous meningitis",
                        "criterion": "carcinomatous meningitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with rapidly progressing tumors, as judged by the investigator",
                "criterions": [
                    {
                        "exact_snippets": "Participants with rapidly progressing tumors",
                        "criterion": "tumor progression rate",
                        "requirement": {
                            "requirement_type": "progression speed",
                            "expected_value": "rapid"
                        }
                    },
                    {
                        "exact_snippets": "as judged by the investigator",
                        "criterion": "investigator assessment of tumor progression",
                        "requirement": {
                            "requirement_type": "assessment authority",
                            "expected_value": "investigator"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants with rapidly progressing tumors",
                        "criterion": "tumor progression rate",
                        "requirement": {
                            "requirement_type": "progression speed",
                            "expected_value": "rapid"
                        }
                    },
                    {
                        "exact_snippets": "as judged by the investigator",
                        "criterion": "investigator assessment of tumor progression",
                        "requirement": {
                            "requirement_type": "assessment authority",
                            "expected_value": "investigator"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* a. Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose",
                "criterions": [
                    {
                        "exact_snippets": "Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose",
                        "criterion": "oral hydrocortisone use",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": "documented adrenal insufficiency diagnosis"
                        }
                    },
                    {
                        "exact_snippets": "Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose",
                        "criterion": "oral hydrocortisone use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 25,
                                "unit": "mg daily total dose"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose",
                                    "criterion": "oral hydrocortisone use",
                                    "requirement": {
                                        "requirement_type": "indication",
                                        "expected_value": "documented adrenal insufficiency diagnosis"
                                    }
                                },
                                {
                                    "exact_snippets": "Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose",
                                    "criterion": "oral hydrocortisone use",
                                    "requirement": {
                                        "requirement_type": "dose",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 25,
                                            "unit": "mg daily total dose"
                                        }
                                    }
                                }
                            ]
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose",
                            "criterion": "oral hydrocortisone use",
                            "requirement": {
                                "requirement_type": "indication",
                                "expected_value": "documented adrenal insufficiency diagnosis"
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Oral hydrocortisone, only for the purposes of a documented adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose",
                            "criterion": "oral hydrocortisone use",
                            "requirement": {
                                "requirement_type": "dose",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 25,
                                    "unit": "mg daily total dose"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC. Examples of inhibitors include: nivolumab, atezolizumab, pembrolizumab, avelumab, cemplimumab, spartalizumab, or durvalumab.",
                "criterions": [
                    {
                        "exact_snippets": "No prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC. Examples of inhibitors include: nivolumab, atezolizumab, pembrolizumab, avelumab, cemplimumab, spartalizumab, or durvalumab.",
                        "criterion": "prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "No prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC. Examples of inhibitors include: nivolumab, atezolizumab, pembrolizumab, avelumab, cemplimumab, spartalizumab, or durvalumab.",
                    "criterion": "prior PD-1 or PD-L1 inhibitor treatment for metastatic NSCLC",
                    "requirement": {
                        "requirement_type": "history of treatment",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation or supraventricular tachycardia), and significant ≥85% carotid artery stenosis",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled intercurrent illness",
                        "criterion": "intercurrent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "angina pectoris",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "cardiac arrhythmia (other than atrial fibrillation or supraventricular tachycardia)",
                        "criterion": "cardiac arrhythmia",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "not atrial fibrillation or supraventricular tachycardia"
                        }
                    },
                    {
                        "exact_snippets": "significant ≥85% carotid artery stenosis",
                        "criterion": "carotid artery stenosis",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 85,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Uncontrolled intercurrent illness",
                                "criterion": "intercurrent illness",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "symptomatic congestive heart failure",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "symptomatic",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "unstable angina pectoris",
                                "criterion": "angina pectoris",
                                "requirement": {
                                    "requirement_type": "stability",
                                    "expected_value": "unstable"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "cardiac arrhythmia (other than atrial fibrillation or supraventricular tachycardia)",
                                "criterion": "cardiac arrhythmia",
                                "requirement": {
                                    "requirement_type": "type",
                                    "expected_value": "not atrial fibrillation or supraventricular tachycardia"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "significant ≥85% carotid artery stenosis",
                                "criterion": "carotid artery stenosis",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 85,
                                        "unit": "%"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of allogeneic organ transplant",
                "criterions": [
                    {
                        "exact_snippets": "History of allogeneic organ transplant",
                        "criterion": "allogeneic organ transplant",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of allogeneic organ transplant",
                    "criterion": "allogeneic organ transplant",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Has a diagnosis of primary immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Has a diagnosis of primary immunodeficiency",
                        "criterion": "primary immunodeficiency",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is receiving chronic systemic steroid therapy",
                        "criterion": "chronic systemic steroid therapy",
                        "requirement": {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to enrollment",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to enrollment",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Has a diagnosis of primary immunodeficiency",
                        "criterion": "primary immunodeficiency",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is receiving chronic systemic steroid therapy",
                        "criterion": "chronic systemic steroid therapy",
                        "requirement": {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to enrollment",
                                "criterion": "immunosuppressive therapy",
                                "requirement": {
                                    "requirement_type": "receiving",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to enrollment",
                                "criterion": "immunosuppressive therapy",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days prior to enrollment"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* b. Inhaled, intranasal, or topical corticosteroids are permitted",
                "criterions": [
                    {
                        "exact_snippets": "Inhaled, intranasal, or topical corticosteroids are permitted",
                        "criterion": "corticosteroid use (inhaled, intranasal, or topical)",
                        "requirement": {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Inhaled, intranasal, or topical corticosteroids are permitted",
                    "criterion": "corticosteroid use (inhaled, intranasal, or topical)",
                    "requirement": {
                        "requirement_type": "permitted",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* No more than six prior lines of systemic therapy for NSCLC",
                "criterions": [
                    {
                        "exact_snippets": "No more than six prior lines of systemic therapy for NSCLC",
                        "criterion": "prior lines of systemic therapy for NSCLC",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "No more than six prior lines of systemic therapy for NSCLC",
                    "criterion": "prior lines of systemic therapy for NSCLC",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 6,
                            "unit": "lines"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Participants with a history of anaphylaxis to beta-lactam antibiotics. Patients may be evaluated for reported history by conducting a history and physical, and a skin test/challenge where appropriate under medical guidance",
                "criterions": [
                    {
                        "exact_snippets": "history of anaphylaxis to beta-lactam antibiotics",
                        "criterion": "anaphylaxis to beta-lactam antibiotics",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "history of anaphylaxis to beta-lactam antibiotics",
                        "criterion": "anaphylaxis to beta-lactam antibiotics",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab. Prophylactic, empiric, or suppressive antibiotics are permitted with sponsor approval",
                "criterions": [
                    {
                        "exact_snippets": "active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab",
                        "criterion": "active systemic infection",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous antibiotics"
                        }
                    },
                    {
                        "exact_snippets": "active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab",
                        "criterion": "active systemic infection",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week prior to nivolumab"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prophylactic, empiric, or suppressive antibiotics are permitted with sponsor approval",
                        "criterion": "use of prophylactic, empiric, or suppressive antibiotics",
                        "requirement": {
                            "requirement_type": "permission",
                            "expected_value": "permitted with sponsor approval"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab",
                                "criterion": "active systemic infection",
                                "requirement": {
                                    "requirement_type": "treatment requirement",
                                    "expected_value": "requiring intravenous antibiotics"
                                }
                            },
                            {
                                "exact_snippets": "active systemic infections requiring intravenous antibiotics within 1 week prior to nivolumab",
                                "criterion": "active systemic infection",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "week prior to nivolumab"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Prophylactic, empiric, or suppressive antibiotics are permitted with sponsor approval",
                            "criterion": "use of prophylactic, empiric, or suppressive antibiotics",
                            "requirement": {
                                "requirement_type": "permission",
                                "expected_value": "permitted with sponsor approval"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants with psychiatric illness/social situations that would limit compliance with study requirements",
                "criterions": [
                    {
                        "exact_snippets": "psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    },
                    {
                        "exact_snippets": "social situations that would limit compliance with study requirements",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    },
                    {
                        "exact_snippets": "social situations that would limit compliance with study requirements",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Unresolved toxicity (grade 2) from previous anti-cancer therapy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)",
                "criterions": [
                    {
                        "exact_snippets": "Unresolved toxicity (grade 2) from previous anti-cancer therapy",
                        "criterion": "toxicity from previous anti-cancer therapy",
                        "requirement": {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        }
                    },
                    {
                        "exact_snippets": "Unresolved toxicity (grade 2) from previous anti-cancer therapy",
                        "criterion": "toxicity from previous anti-cancer therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)",
                        "criterion": "irreversible toxicity not expected to be exacerbated by investigational product",
                        "requirement": {
                            "requirement_type": "reversibility",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)",
                        "criterion": "irreversible toxicity not expected to be exacerbated by investigational product",
                        "requirement": {
                            "requirement_type": "expected exacerbation by investigational product",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Unresolved toxicity (grade 2) from previous anti-cancer therapy",
                                "criterion": "toxicity from previous anti-cancer therapy",
                                "requirement": {
                                    "requirement_type": "resolution status",
                                    "expected_value": "unresolved"
                                }
                            },
                            {
                                "exact_snippets": "Unresolved toxicity (grade 2) from previous anti-cancer therapy",
                                "criterion": "toxicity from previous anti-cancer therapy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "grade"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)",
                                    "criterion": "irreversible toxicity not expected to be exacerbated by investigational product",
                                    "requirement": {
                                        "requirement_type": "reversibility",
                                        "expected_value": false
                                    }
                                },
                                {
                                    "exact_snippets": "irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)",
                                    "criterion": "irreversible toxicity not expected to be exacerbated by investigational product",
                                    "requirement": {
                                        "requirement_type": "expected exacerbation by investigational product",
                                        "expected_value": false
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* d. Prothrombin Time ≤ 1.7x the institutional upper limit of normal (ULN), unless participant is receiving intended anticoagulant therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Prothrombin Time ≤ 1.7x the institutional upper limit of normal (ULN)",
                        "criterion": "Prothrombin Time",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.7,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless participant is receiving intended anticoagulant therapy",
                        "criterion": "intended anticoagulant therapy",
                        "requirement": {
                            "requirement_type": "current therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "not_criteria": {
                        "not_criteria": {
                            "exact_snippets": "unless participant is receiving intended anticoagulant therapy",
                            "criterion": "intended anticoagulant therapy",
                            "requirement": {
                                "requirement_type": "current therapy",
                                "expected_value": true
                            }
                        }
                    }
                },
                "then_criteria": {
                    "exact_snippets": "Prothrombin Time \u00104 1.7x the institutional upper limit of normal (ULN)",
                    "criterion": "Prothrombin Time",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 1.7,
                            "unit": "x ULN"
                        }
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* b. Absolute neutrophil count (ANC) ≥ 1000 per mm3);",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000 per mm3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "per mm3"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1000 per mm3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "per mm3"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* c. Platelet count ≥ 75,000 per mm3, without platelet transfusions for 7 days;",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥ 75,000 per mm3",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "per mm3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "without platelet transfusions for 7 days",
                        "criterion": "platelet transfusions",
                        "requirement": {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e 75,000 per mm3",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "per mm3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "without platelet transfusions for 7 days",
                        "criterion": "platelet transfusions",
                        "requirement": {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* f. AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN",
                "criterions": [
                    {
                        "exact_snippets": "AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN",
                        "criterion": "AST/ALT levels",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x institutional ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN",
                        "criterion": "AST/ALT levels",
                        "requirement": {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x institutional ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN",
                    "criterion": "liver metastases",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN",
                    "criterion": "AST/ALT levels",
                    "requirement": {
                        "requirement_type": "quantity (with liver metastases)",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 5,
                                    "unit": "x institutional ULN"
                                }
                            ]
                        }
                    }
                },
                "else_criteria": {
                    "exact_snippets": "AST/ALT ≤ 2.5x institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN",
                    "criterion": "AST/ALT levels",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 2.5,
                                    "unit": "x institutional ULN"
                                }
                            ]
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with an activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC)",
                        "criterion": "non-small cell lung cancer (NSCLC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC)",
                        "criterion": "non-small cell lung cancer (NSCLC)",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "IV",
                                "recurrent"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains",
                        "criterion": "activating genomic alteration in EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains",
                        "criterion": "activating genomic alteration in EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains",
                        "requirement": {
                            "requirement_type": "gene",
                            "expected_value": [
                                "EGFR",
                                "ALK",
                                "ROS1",
                                "ERBB2"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains",
                        "criterion": "activating genomic alteration in EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains",
                        "requirement": {
                            "requirement_type": "alteration_type",
                            "expected_value": "activating"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* a. Hemoglobin ≥ 9.0 g/dL, with transfusions permissible;",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥ 9.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin \u001e 9.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pulmonary function tests within past 4 months showing DLCO ≥45% of predicted. Adjusted DLCO based on hemoglobin concentration should be used, if available.",
                "criterions": [
                    {
                        "exact_snippets": "Pulmonary function tests within past 4 months",
                        "criterion": "pulmonary function tests",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within past 4 months"
                        }
                    },
                    {
                        "exact_snippets": "DLCO ≥45% of predicted",
                        "criterion": "DLCO (diffusing capacity of the lung for carbon monoxide)",
                        "requirement": {
                            "requirement_type": "percentage of predicted",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adjusted DLCO based on hemoglobin concentration should be used, if available.",
                        "criterion": "DLCO adjustment for hemoglobin",
                        "requirement": {
                            "requirement_type": "adjustment for hemoglobin",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Pulmonary function tests within past 4 months",
                        "criterion": "pulmonary function tests",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within past 4 months"
                        }
                    },
                    {
                        "exact_snippets": "DLCO \u001e45% of predicted",
                        "criterion": "DLCO (diffusing capacity of the lung for carbon monoxide)",
                        "requirement": {
                            "requirement_type": "percentage of predicted",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adjusted DLCO based on hemoglobin concentration should be used, if available.",
                        "criterion": "DLCO adjustment for hemoglobin",
                        "requirement": {
                            "requirement_type": "adjustment for hemoglobin",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* h. Albumin ≥ 2.0 g/dl",
                "criterions": [
                    {
                        "exact_snippets": "Albumin ≥ 2.0 g/dl",
                        "criterion": "albumin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.0,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Albumin \u0013e 2.0 g/dl",
                        "criterion": "albumin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.0,
                                "unit": "g/dl"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* e. Serum bilirubin ≤ 2.0x the institutional ULN, or ≤ 4.0x ULN if confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology) with PI approval.",
                "criterions": [
                    {
                        "exact_snippets": "Serum bilirubin ≤ 2.0x the institutional ULN",
                        "criterion": "serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 4.0x ULN if confirmed Gilbert's syndrome ... with PI approval",
                        "criterion": "serum bilirubin in patients with confirmed Gilbert's syndrome and PI approval",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 4.0x ULN if confirmed Gilbert's syndrome ... with PI approval",
                        "criterion": "serum bilirubin in patients with confirmed Gilbert's syndrome and PI approval",
                        "requirement": {
                            "requirement_type": "condition",
                            "expected_value": "confirmed Gilbert's syndrome"
                        }
                    },
                    {
                        "exact_snippets": "≤ 4.0x ULN if confirmed Gilbert's syndrome ... with PI approval",
                        "criterion": "serum bilirubin in patients with confirmed Gilbert's syndrome and PI approval",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": "PI approval"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum bilirubin \u00102.0x the institutional ULN",
                        "criterion": "serum bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "condition": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "\u0010 4.0x ULN if confirmed Gilbert's syndrome ... with PI approval",
                                    "criterion": "serum bilirubin in patients with confirmed Gilbert's syndrome and PI approval",
                                    "requirement": {
                                        "requirement_type": "condition",
                                        "expected_value": "confirmed Gilbert's syndrome"
                                    }
                                },
                                {
                                    "exact_snippets": "\u0010 4.0x ULN if confirmed Gilbert's syndrome ... with PI approval",
                                    "criterion": "serum bilirubin in patients with confirmed Gilbert's syndrome and PI approval",
                                    "requirement": {
                                        "requirement_type": "approval",
                                        "expected_value": "PI approval"
                                    }
                                }
                            ]
                        },
                        "then_criteria": {
                            "exact_snippets": "\u0010 4.0x ULN if confirmed Gilbert's syndrome ... with PI approval",
                            "criterion": "serum bilirubin in patients with confirmed Gilbert's syndrome and PI approval",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 4.0,
                                    "unit": "x ULN"
                                }
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Expected survival ≥ 4 months",
                "criterions": [
                    {
                        "exact_snippets": "Expected survival ≥ 4 months",
                        "criterion": "expected survival",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Expected survival \u001e= 4 months",
                        "criterion": "expected survival",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Mean QT interval corrected for heart rate (QTc) ≥480 ms calculated from electrocardiograms (EKGs) using Bazett's Correction",
                "criterions": [
                    {
                        "exact_snippets": "Mean QT interval corrected for heart rate (QTc) ≥480 ms ... calculated from electrocardiograms (EKGs) using Bazett's Correction",
                        "criterion": "QTc interval",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "Bazett's Correction"
                        }
                    },
                    {
                        "exact_snippets": "Mean QT interval corrected for heart rate (QTc) ≥480 ms ... calculated from electrocardiograms (EKGs) using Bazett's Correction",
                        "criterion": "QTc interval",
                        "requirement": {
                            "requirement_type": "source",
                            "expected_value": "electrocardiograms (EKGs)"
                        }
                    },
                    {
                        "exact_snippets": "Mean QT interval corrected for heart rate (QTc) ≥480 ms ... calculated from electrocardiograms (EKGs) using Bazett's Correction",
                        "criterion": "QTc interval",
                        "requirement": {
                            "requirement_type": "mean value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Mean QT interval corrected for heart rate (QTc) \u0012480 ms ... calculated from electrocardiograms (EKGs) using Bazett's Correction",
                        "criterion": "QTc interval",
                        "requirement": {
                            "requirement_type": "mean value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Mean QT interval corrected for heart rate (QTc) \u0012480 ms ... calculated from electrocardiograms (EKGs) using Bazett's Correction",
                        "criterion": "QTc interval",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "Bazett's Correction"
                        }
                    },
                    {
                        "exact_snippets": "Mean QT interval corrected for heart rate (QTc) \u0012480 ms ... calculated from electrocardiograms (EKGs) using Bazett's Correction",
                        "criterion": "QTc interval",
                        "requirement": {
                            "requirement_type": "source",
                            "expected_value": "electrocardiograms (EKGs)"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years), or other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI",
                "criterions": [
                    {
                        "exact_snippets": "Active or prior documented autoimmune disease within the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "prior documented"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Active or prior documented autoimmune disease within the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years) ... are allowed after approval from the medical monitor or PI",
                        "criterion": "specific autoimmune conditions (vitiligo, Grave's disease, limited site eczema, limited site plaque psoriasis)",
                        "requirement": {
                            "requirement_type": "systemic treatment requirement (within the past 2 years)",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years) ... are allowed after approval from the medical monitor or PI",
                        "criterion": "specific autoimmune conditions (vitiligo, Grave's disease, limited site eczema, limited site plaque psoriasis)",
                        "requirement": {
                            "requirement_type": "approval from medical monitor or PI",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI",
                        "criterion": "other autoimmune conditions not expected to recur",
                        "requirement": {
                            "requirement_type": "recurrence expectation",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI",
                        "criterion": "other autoimmune conditions not expected to recur",
                        "requirement": {
                            "requirement_type": "approval from medical monitor or PI",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}